Rocket Pharma Shares Climb Premarket After FDA Supports Continuation of Trial
By Robb M. StewartRocket Pharmaceuticals' shares jumped ahead of the opening bell after the biotechnology company said it was aligned with the Food and Drug Administration on the path forward for its pivotal phase 2 trial of a treatment for Danon disease.In premarket trading, the shares were 5.1% h…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.